For the quarter ending 2026-01-31.
| Income Statement | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0* |
| Research and development costs | 93,113 | 141,085 | 95,157 | 148,187* |
| Intangible asset impairment | - | - | - | 0* |
| General and administrative | 2,024,989 | 1,234,966 | 753,148 | 667,254.5* |
| Total operating expenses | 2,118,102 | 1,376,051 | 848,305 | 815,441.5* |
| Loss from operations | -2,118,102 | -1,376,051 | -848,305 | -815,441.5* |
| Interest income | 230,668 | 206,387 | 217,793 | 20,570* |
| Loss on legal settlement | - | - | - | -504,750* |
| Loss on long term asset | - | - | - | 0* |
| Gain on investment in preferred stock tnf | - | - | - | 5,348,933.5* |
| Change in fair value of investment - tnf | - | - | -2,839,000 | -11,476,110.5* |
| Change in fair value of warrant liability | 1,895,865 | -10,474,000 | 243,000 | 4,576,500* |
| Change in fair value of derivative liability | 557,000 | 302,000 | 0 | -756,000* |
| Change in fair value of warrants - tnf | - | - | -4,832,000 | -591,921* |
| Change in fair value of convertible note receivable - femasys | 0 | 392,000 | 912,000 | -79,000* |
| Change in fair value of warrant asset - femasys | -214,000 | -726,000 | -1,215,000 | -240,000* |
| Change in fair value of investment - qcls | 1,725,000 | -2,371,000 | - | - |
| Change in fair value of warrants - qcls | -1,200,000 | 6,050,000 | - | - |
| Gain on legal settlement re-fair value of warrants | 0 | 0 | 106,000 | - |
| Gain on related party investment - qcls | 0 | 2,089,000 | - | - |
| Issuance costs series c convertible preferred stock and warrants | 0 | -1,234,553 | - | - |
| Gain on related party investment - tnf | - | - | 0 | - |
| Loss on issuance of series c convertible preferred stock | 0 | -215,000 | - | - |
| Unrealized loss on marketable securities | -128,939 | -60,663 | -104,463 | 16,579* |
| Other expense | -632 | -95 | -121 | 913* |
| Total other income and (expense), net | 2,864,962 | -6,041,924 | -7,511,791 | -3,684,286* |
| Income tax benefit (expense) | - | - | - | 0* |
| Net income (gain) | 746,860 | -7,417,975 | -8,360,096 | -4,499,727.5* |
| Preferred stock dividends | 98,458 | 96,639 | 0 | -564,879.5* |
| Undistributed income to series b convertible preferred stock | - | - | - | 742,695* |
| Preferred stock accretion | 2,204,657 | 901,996 | 0 | -1,596,702* |
| Net income (gain) attributable to common stockholders | -1,556,255 | -8,416,610 | -8,360,096 | -3,080,841 |
| Basic EPS | -0.17 | -1.24 | -1.23 | -0.475 |
| Diluted EPS | -0.17 | -1.24 | -1.23 | -0.475 |
| Basic Average Shares | 9,262,829 | 6,795,779 | 6,795,779 | 6,485,367 |
| Diluted Average Shares | 9,262,829 | 6,795,779 | 6,795,779 | 6,485,367 |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)